Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
138 results about "Sulphated polysaccharides" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sulphated polysaccharide. Any of a family of antioxidants—e.g., carrageenan, isolated from seaweed, which have therapeutic potential in cyclosporin A-induced hepatotoxicity in rats by reducing lipid peroxidation, and increasing ATPase activity and in treating HIV infection*.
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
InactiveUS20030181416A1Minimizing spreadMinimizing worseningAntibacterial agentsBiocideSulfated polysaccharidesLysosome
Methods and compositions for treating or preventing microbial infection in mammals with sulfated polysaccharides wherein the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by cell receptor binding in the mammal and thereby retains antimicrobial activity in vivo.
Owner:MONASH UNIV
Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
InactiveUS20060040896A1Sufficient degreeGood anti-inflammatory activityOrganic active ingredientsBlood disorderSulfated polysaccharidesMedicine
A method and medicament for anticoagulating a patient with a sulfated polysaccharide mixture that demonstrates enhanced anti-inflammatory activity compared to anticoagulation with unfractionated heparin comprising various combinations of fully anticoagulant unfractionated heparin with 2-O desulfated heparin demonstrating reduced anticoagulant activity but enhanced anti-inflammatory actions. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin in commercially practical quantities for the formulation of an anticoagulant 2-O desulfated heparin and heparin mixture.
Owner:CANTEX PHARMA
Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
InactiveUSRE38743E1Improve bioavailabilityAdministered can be reducedOrganic active ingredientsBiocideThrombotic episodesSulfated polysaccharides
Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis / treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.
Owner:AVENTIS PHARMA SA (US)
Protection of Progenitor Cells and Regulation of Their Differentiation
InactiveUS20110014701A1Improve survivabilityEnhance cryopreservationOrganic active ingredientsSkeletal disorderProgenitorCryopreservation
The present invention relates to the use of polysulfated polysaccharides in combination with progenitor cells to improve the viability of the progenitor cells including improving the cryopreservation of the progenitor cells and provides novel compositions, methods and uses. The present invention also relates to the use of polysulfated polysaccharides to regulate the proliferation and differentiation of progenitor cells.
Owner:PROTEOBIOACTIVES PTY LTD
Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
InactiveUS20050282775A1Sufficient degreeNot induce anti-coagulant activityOrganic active ingredientsAntipyreticHeparin antibodySulfated polysaccharides
A method and medicament for treating inflammation in a patient with a sulfated polysaccharide without inducing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.
Owner:CANTEX PHARMA
Bioconjugates comprising sulfated polysaccharides and their uses
The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can be a heparin-binding polypeptide and / or a positively-charged polypeptide. Also, provided are delivery systems and methods for sustained release of said bioactive polypeptide(s) using said bioconjugates.
Owner:BEN GURION UNIVERSITY OF THE NEGEV
Alga immunopotentiation compound feed for litopenaeus vannamei
ActiveCN103355491AImprove palatabilityFast food intakeAnimal feeding stuffBiotechnologyAntimicrobial action
The invention belongs to the field of aquaculture or feed, relates to a aquaculture feed, and especially relates to an alga immunopotentiation compound feed for litopenaeus vannamei. The invention at first provides an immunity strengthening agent for litopenaeus vannamei feed, and the agent is obtained through enzymatic hydrolysis and fermentation of an alga composite. The alga composite is composed of following components in parts by dried weight: 40 to 50 parts of asparagus, 15 to 25 parts of enteromorpha, 10 to 20 parts of ulva lactuca, 5 to 15 parts of laver and 5 to 15 parts of undaria pinnatifida. The invention further prepares a compound feed for litopenaeus vannamei by utilizing the immunity strengthening agent. The alga immunity strengthening agent contains algae polysaccharide, which has the effect of strengthening animal immunity, acrylic acid, terpenes, brominated phenolic and some sulfocompounds, which have the antiseptic effect, and sulphated polysaccharide, which has the antivirus effect. The litopenaeus vannameis fed on the alga immunopotentiation compound feed have a strong anti-stress performance, the body's immunity ability is improved, survival rate is high and culture benefit is remarkable.
Owner:SUN YAT SEN UNIV
High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
InactiveUS20080004236A1Reducing and avoiding toxicityEnsure adequate treatmentOrganic active ingredientsBiocideMicroorganismSulfated polysaccharides
Methods and compositions for treating or preventing acute or chronic viral infection over a short time interval in mammals with sulfated polysaccharides wherein the polysaccharides have a percent of sulfur with respect to the sugar residue effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by cell receptor binding in the mammal and thereby retains antiviral activity in vivo.
Owner:COMPER WAYNE D
Methods and compositions for treating bleeding disorders
InactiveUS20110172156A1Shorten clotting timeFactor VIIBiocideSulfated polysaccharidesBlood coagulations
Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.
Owner:BAXALTA GMBH
Methods for treating bleeding disorders using sulfated polysaccharides
ActiveUS20090269325A1Shorten clotting timeBiocideSugar derivativesSulfated polysaccharidesCoagulation Disorder
Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
Owner:TAKEDA PHARMA CO LTD
Enzymatic synthesis of sulfated polysaccharides
Heparin is synthesized from a polysaccharide comprised of a 1-4 glycosidically linked alternating polymer of uronic acid and glucosamine residues, wherein the uronic acid is selected from iduronic and glucuronic acid, wherein the glucosamine is partially N-sulfated; by a series of selective reactions catalyzed by recombinant enzymes.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL +1
Sulfated polysaccharide compound and the preparation and use thereof
The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS). The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use.
Owner:PARNELL TECH
Process for preparing tissue factor pathway inhibitor
InactiveUS6300100B1Microorganism based processesRecombinant DNA-technologyBiotechnologySulfated polysaccharides
In a process for preparing Tissue Factor Pathway Inhibitor (TFPI) by the genetically engineered technique by the use of a transformed animal cell wherein a DNA encoding human TFPI is introduced, the improvement which comprises culturing said transformed animal cell in a culture medium supplemented with a sulfated polysaccharide to protect an intact TFPI produced by said transformed animal cell from cleavage by proteases present in the culture medium.
Owner:JURIDICAL FOUND THE CHEMO SERO THERAPEUTIC RES INST
Oral Care Compositions
ActiveUS20150320654A1Minimizes cost and complexityImprove rheologyCosmetic preparationsToilet preparationsSulfated polysaccharidesDentistry
Oral care composition comprises a stannous ion source and a thickener comprising at least 2 agents selected from the group consisting of: i) a linear sulfated polysaccharide; ii) a natural gum; iii) and a non-ionic cellulose derivative. A method for treating the oral cavity comprises administering to the oral cavity the oral care composition.
Owner:THE PROCTER & GAMBLE COMPANY
Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
InactiveUS20130273096A1Suppressing glycocalyx degredationSuppressing vascular damageEsterified saccharide compoundsBiocideSulfated polysaccharidesMedicine
Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.
Owner:DANIELS BRUCE A
Resorption Enhancers As Additives To Improve The Oral Formulation Of Non-Anticoagulant Sulfated Polysaccharides
ActiveUS20130035288A1Enhancing coagulation of bloodOrganic active ingredientsBiocideEpithelial barrierSulfated polysaccharides
Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.
Owner:TAKEDA PHARMA CO LTD
Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses
InactiveUS20050004071A1Minimize delayMinimize symptomAntibacterial agentsOrganic active ingredientsSulfated polysaccharidesLysosome
This invention relates to methods for treating, preventing or managing coronavirus infections in mammals using sulfated polysaccharides. More particularly, this invention relates to methods of treating, preventing or managing infection by coronaviruses, particularly viral infections leading to or causing diseases such as the newly discovered Severe Acute Respiratory Syndrome (“SARS”). The invention involves the use of sulfated polysaccharides which are abundant, non-toxic and inexpensive and which are potent antivirals in vivo.
Owner:MONASH UNIV
Seed Growth Enhancer Compositions
InactiveUS20160007590A1Increase heightUniform integrityBiocideFertilising methodsAlcoholSulfated polysaccharides
The present invention comprises bio-degradeable seed growth enhancer compositions that provide enhanced seed protection and propagation characteristics that can be formulated and tailored to the plant or crop species for best results. The formulations comprise a naturally - derived hydrophilic protein hydrogel with a sulfated or neutral non-sulfated polysaccharide incorporated therein together with an azeotropic drying agent. The drying agent is a preferably a low molecular weight alcohol or ketone which insures uniform application and adherence qualities of the coating when the hydrogel is dried onto the seed.
Owner:SCHULTZ THOMAS M +1
Method for treating thrombotic disorders using sulfated polysaccharides
InactiveUS20090098185A1Good coagulationProlong clotting timeOrganic active ingredientsBiocideFucoidanSulfated polysaccharides
Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.
Owner:AVIGEN
Hydrogel system comprising spatially separated bioactive polypeptides
ActiveUS20150051148A1Peptide/protein ingredientsBone-inducing factorSulfated polysaccharidesDamages tissue
The present invention provides a multi-compartment hydrogel, and a sulfated polysaccharide and at least two bioactive polypeptides capable of binding said sulfated polysaccharide, for use in repair or regeneration of a damaged tissue in a mammal. Also provided is a method for constructing the multi-compartment hydrogel. The present invention also provides a method for the repair or regeneration of a damaged tissue in a mammal, and a kit for constructing a multi-compartment hydrogel.
Owner:BEN GURION UNIVERSITY OF THE NEGEV
Methods for Treating Bleeding Disorders
Owner:BAXALTA GMBH
Enteromorpha prolifera oligosaccharide with auxiliary blood sugar decreasing function and preparation method thereof
ActiveCN105567762AReduce dosageImprove enzymatic hydrolysis efficiencyFermentationSulfated polysaccharidesPentagalacturonic acid
The invention discloses an enteromorpha prolifera oligosaccharide with an auxiliary blood sugar decreasing function and a preparation method of the enteromorpha prolifera oligosaccharide. The preparation method is characterized by comprising the steps of extracting enteromorpha prolifera sulphated polysaccharide by assisting of using microwaves; degreasing, removing protein and pigments; adding polygalacturonase, alpha-L-rhamnosidase and xylanase in sequence to perform enzymolysis; after enzyme denaturation, removing enzymes and undegraded polysaccharide by using ethanol; enabling a centrifugal supernatant to pass through a molecular sieve to obtain a retentate; freezing and drying the retentate to obtain the enteromorpha prolifer aactive oligosaccharide. Verified by pharmacodynamics of animals, enteromorpha prolifera oligosaccharide can remarkably decrease a blood sugar value of a high blood sugar type mouse. Non-specific commercial enzymes are used, the preparation method disclosed by the invention is simple in process route, highly efficient, and environment friendly; the preparation quantity of the oligosaccharide is improved, and the consumption of enzymes and the production cost are reduced; the preparation method is an effective method for preparing the enteromorpha prolifera active oligosaccharide.
Owner:福州海晟特膳生物科技有限公司
Pre-Emergent Seed Coatings and Growth Stimulator Compositions
InactiveUS20150320033A1Improve propertiesSuperior osmoticBiocideInorganic active ingredientsSulfated polysaccharidesGelatin
A bio-degradable seed coating composition for enhanced seed protection and propagation consists of a gelatin-based hydrogel formulation consisting of a naturally derived, hydrophilic protein, a sulfated or non-sulfated polysaccharide, a divalent cationic salt, and an azeotropic drying agent. The coating is readily applied to the seed and has enhanced drying functionality. The composition adheres to the seed surface and protects the seed during storage for improved shelf life while still being readily hydrated and water absorbent once planted in the respective growing medium.
Owner:SCHULTZ THOMAS MICHAEL +2
Oligosaccharides derived from fucoidan
The present invention provides a fucoidan-derived low molecular weight compound with a good quality of taste, which has a specified structure and function and is free from problems in absorption, antigenicity, uniformity, an anticoagulant activity and so on, which problems arise when developing fucoidan, a sulfated polysaccharide having an extremely large molecular weight, as drugs or health foods. As a result of analyzing low molecular weight compounds obtained by acid hydrolysis of fucoidan, the inventors have identified fucoidan oligosaccharides (I) to (XI). Further, these oligosaccharides have been found to have anti-obesity and / or blood glucose elevation suppressing effects through inhibition of carbohydrate and / or lipid absorption as a result of α-glucosidase inhibition and / or lipase inhibition.
Owner:SUNTORY HLDG LTD +1
Use of oversulfated polysaccharides as inhibitors of HIV
InactiveUS7268122B2Reduce riskEnhanced inhibitory effectOrganic active ingredientsBiocideDiseaseSulfation
Owner:GLYCORES 2000 SRL
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
InactiveUS20040009953A1Retain activitySufficient retentionOrganic active ingredientsBiocideMicroorganismSulfated polysaccharides
Methods and compositions for treating or preventing microbial infection in mammals with sulfated polysaccharides wherein the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by cell receptor binding in the mammal and thereby retains antimicrobial activity in vivo.
Owner:MONASH UNIV
Method for preparing sulodexide raw material from heparin byproduct by adopting ethanol precipitation process
The invention discloses a method for preparing a sulodexide raw material from a heparin byproduct by adopting an ethanol precipitation process. The method comprises the following steps: dissolving the heparin byproduct, adjusting a liquid to have a high pH value by sodium hydroxide, performing low-temperature precipitation by a proper amount of ethanol, and removing precipitate to obtain a sulphated polysaccharide liquid; adjusting the sulphated polysaccharide liquid to have a low pH value by hydrochloric acid, performing low-temperature precipitation by a proper amount of ethanol, and removing precipitate to obtain a sulphated polysaccharide liquid; and adjusting the liquid to be neutral by sodium hydroxide, performing room-temperature precipitation by a proper amount of ethanol, and drying precipitate to obtain the sulodexide raw material. The method is simple in process, low in cost, easy to realize and suitable for industrialized production.
Owner:SHENZHEN HEPALINK PHARMA GRP CO LTD
Method for treating thrombotic disorders using sulfated polysaccharides
InactiveUS20080107678A1Enhancing coagulation of bloodProlong clotting timeBiocideSurgerySulfated polysaccharidesFucoidan
Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.
Owner:BAXTER INT INC +1
Cohesive coprecipitates of sulfated polysaccharide and fibrillar protein and use thereof
InactiveUS20060110426A1Improve the environmentEasy to useBiocideAerosol deliverySulfated polysaccharidesBiopolymer
The present invention concerns cohesive biopolymer gels comprising coprecipitates of sulfated polysaccharides and fibrillar proteins, exemplified by coprecipitates of dextran sulfate and gelatin, useful for clinical applications including as implants for tissue engineering as well as in biotechnology. The cohesive biopolymer gels according to the present invention may be used clinically either per se or as a scaffold for a cell-bearing implant, as a depot for sustained release of bioactive agents, or for research and biotechnology.
Owner:NVR LABS
Pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
InactiveUS20100137400A1Improve bioavailabilityLow production costBiocideOrganic chemistryHMG-CoA reductaseSulfation
The present invention relates to improved pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an HMG-CoA reductase inhibitor, and more particularly Fluvastatin, Atorvastatin or salts thereof in combination with a linear sulphated polysaccharide such as Carrageenan and a method for the preparation thereof.
Owner:PHARMATHEN
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com